Follow-up studies of treatment for hepatitis C virus infection among injection drug users

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Dalgard, Olav ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

CONFERENCE PAPER; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; REINFECTION; RELAPSE; VIRUS DETECTION; VIRUS TRANSMISSION;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; RECURRENCE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 16844379638     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427449     Document Type: Conference Paper

References (21)

1. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31(Suppl 1):80-3.
2. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(Suppl 1):S93-8.
3. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38:864-70.
4. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345:215-7.
5. Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999; 31(Suppl 1):259-63.
6. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-40.
7. Payen JL, Izopet J, Barange K, Puel J, Selves J, Pascal JP. Reinfection par le virus de l'hepatite C apres une injection intraveineuse de drogue. Gastroenterol Clin Biol 1998; 22:469-70.
8. Asselah T, Vidaud D, Doloy A, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52:900-2.
9. Dalgard O, Bjøro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
10. Bell H, Hellum K, Harthug S, et al. Genotype, viral load, and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 1997; 29:17-22.
11. Bell H, Hellum K, Harthug S, et al. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scand J Gastroenterol 1999; 34:194-8.
12. Giannini C, Giannelli F, Monti M, et al. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med 1999; 134:68-73.
13. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996; 28:27-9.
14. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51:692-7.
15. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35:3274-7.
16. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-83.
17. McHutchison JG, Davis GL, Esteban JI, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2B alone or in combination with ribavirin. Hepatology 2001;34:244A.
18. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-9.
19. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
20. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-32.
21. Ravndal E, Vaglum P. Psychopathology, treatment completion and 5 years outcome. A prospective study of drug abusers. J Subst Abuse Treat 1998; 15:135-42.